TIADYLT ER
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- TIADYLT ER
- Generic name
- DILTIAZEM HYDROCHLORIDE
- Manufacturer
- Zydus Lifesciences Limited
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- d88e3546-3984-4dc9-893a-a29e95804550
- SPL ID
- 302fc306-6fbe-4567-b5ce-dcc5a45ba894
- Version
- 5
- Effective date
- 2025-05-02
- Source export date
- 2026-09-28
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/fd09911bd1bc81f7f2faeb048e63855fe224e494376ae919a0035190e315c050/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:18:24
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 206641 | derived:openfda.application_number |
| application number | ANDA206641 | openfda.application_number | |
| brand name | TIADYLT ER | openfda.brand_name | |
| generic name | DILTIAZEM HYDROCHLORIDE | openfda.generic_name | |
| manufacturer name | Zydus Lifesciences Limited | openfda.manufacturer_name | |
| ndc | package | 70771-1036-9 | openfda.package_ndc |
| ndc | package | 70771-1035-1 | openfda.package_ndc |
| ndc | package | 70771-1038-3 | openfda.package_ndc |
| ndc | package | 70771-1040-9 | openfda.package_ndc |
| ndc | package | 70771-1035-0 | openfda.package_ndc |
| ndc | package | 70771-1035-5 | openfda.package_ndc |
| ndc | package | 70771-1039-5 | openfda.package_ndc |
| ndc | package | 70771-1039-1 | openfda.package_ndc |
| ndc | package | 70771-1035-9 | openfda.package_ndc |
| ndc | package | 70771-1036-3 | openfda.package_ndc |
| ndc | package | 70771-1036-1 | openfda.package_ndc |
| ndc | package | 70771-1037-5 | openfda.package_ndc |
| ndc | package | 70771-1040-1 | openfda.package_ndc |
| ndc | package | 70771-1037-1 | openfda.package_ndc |
| ndc | package | 70771-1037-9 | openfda.package_ndc |
| ndc | package | 70771-1039-0 | openfda.package_ndc |
| ndc | package | 70771-1038-1 | openfda.package_ndc |
| ndc | package | 70771-1039-9 | openfda.package_ndc |
| ndc | package | 70771-1036-0 | openfda.package_ndc |
| ndc | package | 70771-1040-0 | openfda.package_ndc |
| ndc | package | 70771-1035-3 | openfda.package_ndc |
| ndc | package | 70771-1036-5 | openfda.package_ndc |
| ndc | package | 70771-1038-9 | openfda.package_ndc |
| ndc | package | 70771-1040-5 | openfda.package_ndc |
| ndc | package | 70771-1040-3 | openfda.package_ndc |
| ndc | package | 70771-1038-0 | openfda.package_ndc |
| ndc | package | 70771-1038-5 | openfda.package_ndc |
| ndc | package | 70771-1037-3 | openfda.package_ndc |
| ndc | package | 70771-1037-0 | openfda.package_ndc |
| ndc | package | 70771-1039-3 | openfda.package_ndc |
| ndc | product | 70771-1040 | openfda.product_ndc |
| ndc | product | 70771-1036 | openfda.product_ndc |
| ndc | product | 70771-1038 | openfda.product_ndc |
| ndc | product | 70771-1037 | openfda.product_ndc |
| ndc | product | 70771-1039 | openfda.product_ndc |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Cardiac Conduction: Diltiazem hydrochloride prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (13 of 3007 patients or 0.43%). Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal's angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem. Congestive Heart Failure: Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dP/dt). An acute study of oral diltiazem in patients with impaired ventricular function (ejection fraction 24% ± 6%) showed improvement in indices of ventricular function without significant decrease in contractile function (dP/dt). Worsening of congestive heart failure has been reported in patients with preexisting impairment of ventricular function. Experience with the use of diltiazem hydrochloride in combination with beta-blockers in patients with impaired ventricular function is limited. Caution should be exercised when using this combination. Hypotension: Decreases in blood pressure associated with diltiazem hydrochloride therapy may occasionally result in symptomatic hypotension. Acute Hepatic Injury: Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed in clinical studies. Such elevations were usually transient and frequently resolved even with continued diltiazem treatment. In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, and SGPT, and other phenomena consistent with acute hepatic injury have been noted. These reactions tended to occur early after therapy initiation (1 to 8 weeks) and have been reversible upon discontinuation of drug therapy. The relationship to diltiazem hydrochloride is uncertain in some cases but probable in some (see PRECAUTIONS ).
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Serious adverse reactions have been rare in studies with Tiadylt, as well as with other diltiazem formulations. It should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities have usually been excluded from these studies. A total of 256 hypertensives were treated for between 4 and 8 weeks; a total of 207 patients with chronic stable angina were treated for 3 weeks with doses of Tiadylt ranging from 120 to 540 mg once daily. Two patients experienced first-degree AV block at the 540 mg dose. The following table presents the most common adverse reactions, whether or not drug-related, reported in placebo-controlled trials in patients receiving Tiadylt up to 360 mg and up to 540 mg with rates in placebo patients shown for comparison. MOSTCOMMONADVERSEEVENTSINDOUBLE-BLINDPLACEBO-CONTROLLEDHYPERTENSIONTRIALS Adverse events occurring in treated patients at 2% or more than placebo-treated patients. Placebo Tiadylt Adverse Events (COSTART Term) n=57 # pts (%) Up to 360 mg n=149 # pts (%) 480 to 540 mg n=48 # pts (%) edema, peripheral 1 (2) 8 (5) 7 (15) dizziness 4 (7) 6 (4) 2 (4) vasodilation 1 (2) 5 (3) 1 (2) dyspepsia 0 (0) 7 (5) 0 (0) pharyngitis 2 (4) 3 (2) 3 (6) rash 0 (0) 3 (2) 0 (0) infection 2 (4) 2 (1) 3 (6) diarrhea 0 (0) 2 (1) 1 (2) palpitations 0 (0) 2 (1) 1 (2) nervousness 0 (0) 3 (2) 0 (0) headache 1 (2) 13 (8) 4 (8) edema, peripheral 1 (2) 3 (2) 5 (10) pain 1 (2) 10 (6) 3 (6) dizziness 0 (0) 5 (3) 5 (10) asthenia 0 (0) 1 (1) 2 (4) dyspepsia 0 (0) 2 (1) 3 (6) dyspnea 0 (0) 1 (1) 3 (6) bronchitis 0 (0) 1 (1) 2 (4) AV block 0 (0) 0 (0) 2 (4) infection 0 (0) 2 (1) 1 (2) flu syndrome 0 (0) 0 (0) 1 (2) cough increase 0 (0) 2 (1) 1 (2) extrasystoles 0 (0) 0 (0) 1 (2) gout 0 (0) 2 (1) 1 (2) myalgia 0 (0) 0 (0) 1 (2) impotence 0 (0) 0 (0) 1 (2) conjunctivitis 0 (0) 0 (0) 1 (2) rash 0 (0) 2 (1) 1 (2) abdominal enlargement 0 (0) 0 (0) 1 (2) In addition, the following events have been reported infrequently (less than 2%) in clinical trials with other diltiazem products: Cardiovascular: Angina, arrhythmia, AV block (second- or third-degree), bundle branch block, congestive heart failure, ECG abnormalities, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles. Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tinnitus, tremor. Gastrointestinal: Anorexia, constipation, diarrhea, dry mouth, dysgeusia, mild elevations of SGOT, SGPT, LDH, and alkaline phosphatase (see WARNINGS, Acute Hepatic Injury ), nausea, thirst, vomiting, weight increase. Dermatological: Petechiae, photosensitivity, pruritus. Other: Albuminuria, allergic reaction, amblyopia, asthenia, CPK increase, crystalluria, dyspnea, edema, epistaxis, eye irritation, headache, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, neck rigidity, nocturia, osteoarticular pain, pain, polyuria, rhinitis, sexual difficulties, gynecomastia. In addition, the following postmarketing events have been reported infrequently in patients receiving diltiazem hydrochloride: acute generalized exanthematous pustulosis, alopecia, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, photosensitivity (including lichenoid keratosis and hyperpigmentation at sun-exposed skin areas), leukopenia, purpura, retinopathy, and thrombocytopenia. In addition, events such as myocardial infarction have been observed which are not readily distinguishable from the natural history of the disease in these patients. A number of well-documented cases of generalized rash, characterized as leukocytoclastic vasculitis, have been reported. However, a definitive cause and effect relationship between these events and diltiazem hydrochloride therapy is yet to be established. To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table ID="ID41" width="583"><caption> MOSTCOMMONADVERSEEVENTSINDOUBLE-BLINDPLACEBO-CONTROLLEDHYPERTENSIONTRIALS<footnote ID="ID410">Adverse events occurring in treated patients at 2% or more than placebo-treated patients.</footnote></caption><col width="177"/><col width="135"/><col width="135"/><col width="135"/><tbody><tr><td valign="top" styleCode=" Toprule"/><td valign="top" styleCode=" Toprule Botrule" align="center"><content styleCode="underline">Placebo</content> </td><td colspan="2" valign="top" styleCode=" Toprule Botrule" align="center"><content styleCode="underline">Tiadylt</content> </td></tr><tr><td styleCode=" Botrule" align="left"> Adverse Events (COSTART Term) </td><td valign="top" styleCode=" Botrule" align="center"> n=57 # pts (%) </td><td valign="top" styleCode=" Botrule" align="center"> Up to 360 mg n=149 # pts (%) </td><td valign="top" styleCode=" Botrule" align="center"> 480 to 540 mg n=48 # pts (%) </td></tr><tr><td valign="top" align="left"> edema, peripheral </td><td valign="top" align="center"> 1 (2) </td><td valign="top" align="center"> 8 (5) </td><td valign="top" align="center"> 7 (15) </td></tr><tr><td valign="top" align="left"> dizziness </td><td valign="top" align="center"> 4 (7) </td><td valign="top" align="center"> 6 (4) </td><td valign="top" align="center"> 2 (4) </td></tr><tr><td valign="top" align="left"> vasodilation </td><td valign="top" align="center"> 1 (2) </td><td valign="top" align="center"> 5 (3) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> dyspepsia </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 7 (5) </td><td valign="top" align="center"> 0 (0) </td></tr><tr><td valign="top" align="left"> pharyngitis </td><td valign="top" align="center"> 2 (4) </td><td valign="top" align="center"> 3 (2) </td><td valign="top" align="center"> 3 (6) </td></tr><tr><td valign="top" align="left"> rash </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 3 (2) </td><td valign="top" align="center"> 0 (0) </td></tr><tr><td valign="top" align="left"> infection </td><td valign="top" align="center"> 2 (4) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 3 (6) </td></tr><tr><td valign="top" align="left"> diarrhea </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> palpitations </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> nervousness </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 3 (2) </td><td valign="top" align="center"> 0 (0) </td></tr><tr><td valign="top" align="left"> headache </td><td valign="top" align="center"> 1 (2) </td><td valign="top" align="center"> 13 (8) </td><td valign="top" align="center"> 4 (8) </td></tr><tr><td valign="top" align="left"> edema, peripheral </td><td valign="top" align="center"> 1 (2) </td><td valign="top" align="center"> 3 (2) </td><td valign="top" align="center"> 5 (10) </td></tr><tr><td valign="top" align="left"> pain </td><td valign="top" align="center"> 1 (2) </td><td valign="top" align="center"> 10 (6) </td><td valign="top" align="center"> 3 (6) </td></tr><tr><td valign="top" align="left"> dizziness </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 5 (3) </td><td valign="top" align="center"> 5 (10) </td></tr><tr><td valign="top" align="left"> asthenia </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (1) </td><td valign="top" align="center"> 2 (4) </td></tr><tr><td valign="top" align="left"> dyspepsia </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 3 (6) </td></tr><tr><td valign="top" align="left"> dyspnea </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (1) </td><td valign="top" align="center"> 3 (6) </td></tr><tr><td valign="top" align="left"> bronchitis </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (1) </td><td valign="top" align="center"> 2 (4) </td></tr><tr><td valign="top" align="left"> AV block </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (4) </td></tr><tr><td valign="top" align="left"> infection </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> flu syndrome </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> cough increase </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> extrasystoles </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td align="left"> gout </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> myalgia </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> impotence </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> conjunctivitis </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" align="left"> rash </td><td valign="top" align="center"> 0 (0) </td><td valign="top" align="center"> 2 (1) </td><td valign="top" align="center"> 1 (2) </td></tr><tr><td valign="top" styleCode=" Botrule" align="left"> abdominal enlargement </td><td valign="top" styleCode=" Botrule" align="center"> 0 (0) </td><td valign="top" styleCode=" Botrule" align="center"> 0 (0) </td><td valign="top" styleCode=" Botrule" align="center"> 1 (2) </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.